Population Fraction of Cervical Neoplasia Attributable to High-Risk Human Papillomaviruses

Abstract

CIN3 may be a valid surrogate efficacy end point for HPV vaccination studies, but the associated causality of multiple hrHPV exposures needs to be unambigously defined.